Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series by McAdoo, SP et al.
Concise report doi:10.1093/rheumatology/kew199
Ofatumumab for B cell depletion therapy in ANCA-
associated vasculitis: a single-centre case series
Stephen P. McAdoo1,2, Rachna Bedi1, Ruth Tarzi2, Megan Griffith1,2,
Charles D. Pusey1,2,* and Thomas D. Cairns1,*
Abstract
Objectives. B cell depletion is an effective treatment strategy in ANCA-associated vasculitis (AAV).
Ofatumumab is a fully humanized anti-CD20 mAb that has shown efficacy in the treatment of haemato-
logical malignancy and RA. The use of ofatumumab in the treatment of AAV has not previously been
reported.
Methods. This study was based on a case series of eight patients who received ofatumumab, in con-
junction with low-dose CYC and oral steroids, in the treatment of AAV.
Results. Eight patients received ofatumumab: seven for remission induction in active disease (three
relapsing; four with new disease) and one for remission maintenance. B cell depletion was achieved in
all patients by 1 month, and was sustained for at least 6 months. All patients with active disease achieved
clinical remission (BVAS of zero, or BVAS45 if all scores due to persistent urinary abnormalities in the
presence of stable or improving renal function) by 3 months. This was associated with a rapid fall in ANCA
titres, reduced inflammatory responses and improvements in renal function. At 12 months, three patients
had repopulated B cells associated with the recurrence of circulating ANCAs, although no patients experi-
enced major clinical relapse in the first 24 months. No unexpected side effects were observed.
Conclusion. Treatment with ofatumumab resulted in similar serological and clinical responses to those
seen in previous cohorts treated at our centre with a comparable CS, CYC and rituximab-based regimen.
Ofatumumab should be considered an alternative B cell depleting agent in patients who are intolerant of,
or unresponsive to, rituximab.
Key words: ANCA, vasculitis, B cells, biologic therapies, microscopic polyangiitis, granulomatosis with
polyangiitis
Rheumatology key message
. Ofatumumab is a potential alternative to rituximab for B cell depletion therapy in ANCA-associated vasculitis.
Introduction
Targeted B cell depletion has emerged as an effective
treatment strategy in ANCA-associated vasculitis (AAV),
both as remission-induction and remission-maintenance
therapy [13]. All reported series and trials using this
approach have employed rituximab, a murine chimeric
mAb directed against the transmembrane calcium
channel CD20, which results in predominantly antibody-
dependent cellular cytotoxicity-mediated depletion of cir-
culating B lymphocytes expressing this molecule.
Ofatumumab is a fully humanized mAb directed against
a distinct extracellular epitope of CD20, which has slower
dissociation kinetics compared with rituximab, and which
has been shown to be a more potent activator of comple-
ment-dependent cytotoxicity in vitro [4]. It is licensed for
use in haematological malignancies, where it has shown
biologic activity in rituximab-resistant disease [5, 6].
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Notably, ofatumumab has also shown efficacy in rituxi-
mab-resistant cases of paediatric nephrotic syndrome
[7], and has demonstrated biological activity in RA [810].
Here, we report our preliminary experience using ofatu-
mumab for the treatment of AAV. This was based on ex-
perience of ofatumumab use in patients with LN who had
demonstrated anaphylactic reactions to rituximab, and
was initially used in a patient with AAV who had similarly
demonstrated an anaphylactic reaction to rituximab. This
approach was subsequently extended to include rituxi-
mab-naı¨ve patients, based on our positive initial experi-
ence. Our treatment regimen using ofatumumab was
based on our previously published protocol for using ritux-
imab (in conjunction with low-dose pulsed i.v. CYC and a
reduced steroid dose) [11]. This regimen, which has been
standard of care for AAV with renal involvement at our
centre since 2006, is associated with low cumulative ex-
posure to CYC and steroids, and prolonged disease-free
remission. In the present study, ofatumumab was substi-
tuted in for rituximab at the initiation of remission-
induction therapy, and we report 2-year outcomes.
Methods
This study is based on a case series of eight patients
treated between November 2012 and July 2013 at our
centre, who received ofatumumab as a component of
their treatment regimen for AAV. Ofatumumab was initially
used at our centre on compassionate grounds for patients
who were intolerant to rituximab due to anaphylaxis, but
for whom anti-CD20 treatment was deemed appropriate
(both in LN and AAV; the lupus cohort will be reported
separately). Following our positive initial experience in
these patients, rituximab-naive patients with AAV were
also treated. Ofatumumab use was off-label, based on
evidence supporting the use of anti-CD20 therapy in
AAV at that time, and predated the licensing of rituximab
for this indication in 2013 (when use of the latter agent was
similarly off-label). Use of ofatumumab was guided by
expert opinion at our centre and approved by the
Glomerulonephritis Protocol and Research Group at
Imperial College Healthcare National Health Service Trust.
The treatment protocol was based on our previously
reported regimen using low-dose pulsed i.v. CYC and
steroids, in conjunction with anti-CD20 treatment [11],
and this has been standard of care at our centre since
2006. Herein, ofatumumab 2  700 mg was substituted
in for rituximab 2  1 g administered at days 0 and 14. The
additional components of the protocol included i.v. CYC
10 mg/kg administered at days 0 and 14 (maximum
750 mg each) and then every 14 days for a further four
doses (maximum 500 mg each). Oral prednisolone 1 mg/
kg was started at day 0 (maximum 60 mg) and reduced
sequentially to achieve a dose of 10 mg by week 13.
Further steroid weaning was at the discretion of the treat-
ing physician. Where patients were treated for relapsing
disease or for remission maintenance, or had received
pulsed i.v. methylprednisolone before referral to our
centre, modified doses of either steroids or CYC may
have been used. Therapeutic plasma exchange was
offered for patients who presented with dialysis-
dependent renal failure. In these cases, administration of
the first dose of ofatumumab was delayed until comple-
tion of plasma exchange. Maintenance therapy com-
menced at 3 months, after completion of cytotoxic
therapy, or earlier in those who received modified doses
of CYC. First-line maintenance was with AZA; MMF was
used in those who were intolerant. Patients received
prophylactic co-trimoxazole for 3 months, proton pump
inhibitors and bone protection with calcium/D3. Patients
from high-risk groups were also given prophylaxis against
tuberculosis with isoniazid and pyridoxine.
Patients were regularly assessed using both clinical and
laboratory measures. Disease activity was scored using
version 3 of the BVAS [12]. Laboratory assessments
included monitoring of the B cell count, ANCA titre,
serum CRP and renal function as determined by serum
creatinine measurements.
Informed consent was provided prior to initiation of
therapy in all cases. In accordance with the UK National
Health Service Research Ethics Committee guidelines,
ethics approval was not required for this report, because
all treatment decisions were made prior to this evaluation,
and were part of a formal change in our standard-care
regimen
Results
Individual patient characteristics and details of the treat-
ments are summarized in Table 1. The demographic fea-
tures of this cohort are in keeping with that of the
population of patients with vasculitis seen at our centre.
The cohort included a mixture of AAV disease pheno-
types, including granulomatosis with polyangiitis, micro-
scopic polyangiitis and eosinophilic granulomatosis with
polyangiitis (EGPA). Five of the six patients with renal in-
volvement had confirmatory renal biopsies demonstrating
necrotizing or crescentic glomerulonephritis. Two patients
were ANCA-negative; of these, one had a renal biopsy
confirming necrotizing glomerulonephritis consistent with
small-vessel vasculitis (case 5). The second ANCA-
negative patient had an established diagnosis of EGPA
based on prior presentation with adult-onset asthma, si-
nusitis, biopsy-proven granulomatous panniculitis and
peripheral blood eosinophilia (case 3). Two patients pre-
sented with dialysis-dependent renal failure and received
plasma exchange in addition to medical therapy with anti-
CD20, CYC and CSs. Three patients were treated for
relapsing disease, one for maintenance of remission in
EGPA (in response to rising ANCA titres and eosinophilia
without clinical manifestations), and four patients for new
disease presentations. Of the two patients who had pre-
viously received anti-CD20, one had demonstrated an
anaphylactic infusion reaction to rituximab (case 1) and
on this basis was treated with ofatumumab.
All patients experienced B cell depletion by 1 month, as
defined by an absolute B cell count of<5 cells/ml (Fig. 1A).
B cell depletion was sustained until at least 6 months in all
patients. This was associated with a rapid reduction in
ANCA titres (Fig. 1B). All patients with active disease
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achieved clinical remission by 3 months, as defined by
BVAS of zero or BVAS45 if all scores were due to per-
sistent haematuria or proteinuria in the presence of stable
or improving renal function as measured by serum creatin-
ine (Fig. 1C). This was associated with a reduced acute
phase response (Fig. 1D) and the ability to taper CS treat-
ment (Fig. 1E). The median total dose of CYC adminis-
tered was 3.05 g. In those patients with renal
involvement (n = 6), there was improvement in renal func-
tion in five cases (Fig. 1F). One patient who presented with
dialysis-dependent renal failure and 50% interstitial fibro-
sis and tubular atrophy on renal biopsy, did not recover
independent renal function (case 8). His other disease
manifestations did, however, resolve (BVAS 0 at
3 months), and he remained in stable remission, allowing
successful renal transplantation at 21 months. This was
with alemutuzumab-based induction and tacrolimus
monotherapy for immunosuppression [13]. Accordingly,
he remains lymphocyte deplete, with no clinical features
of vasculitis and no evidence of disease recurrence on
allograft surveillance biopsy.
At 12 months, three patients had repopulated B cells
(absolute count>20 cells/ml), in all cases associated with
recurrence of circulating ANCA (cases 2, 6 and 7),
FIG. 1 Serological and clinical responses at 0, 1, 3, 6, 12, 18 and 24 months following ofatumumab treatment
Box-and-whisker plots describe the median, interquartile range and minimum and maximum values. One patient who
presented with dialysis-dependent renal failure and 50% interstitial fibrosis and tubular atrophy on renal biopsy, who did
not recover independent renal function, has been excluded from Fig. 1F. Similarly, this case has been censored from all
other figures following renal transplantation at 21 months. BCC: B cell count.
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although no patients experienced clinical relapse in the
first year. At 24 months, a further patient reconstituted B
cells with weakly positive ANCA, though without clinical
features of relapse (case 1). In those patients who recon-
stituted B cells over the 2-year follow-up period, the
median time to reconstitution was 11.8 months. After
2 years follow-up, one ANCA-negative patient with
EGPA (case 3) experienced two minor relapses, in the
absence of B cell reconstitution, at 15 and 21 months,
which were treated with oral CSs only.
We did not detect any unexpected side effects: one
patient experienced a minor infusion reaction to ofatumu-
mab; three patients had infectious complications (in total
there were three urinary tract infections, one upper
respiratory tract infection and one lower respiratory tract
infection); one patient had a transient episode of neutro-
penia not associated with infection. There were no atyp-
ical or opportunistic infections, and we did not detect any
episodes of hypogammaglobulinaemia or hepatitis
reactivation.
Conclusion
This is the first reported use of ofatumumab in AAV, and our
preliminary data suggest that this agent results in similar
serological and clinical responses to those of previous co-
horts treated with a comparable CS, CYC and rituximab-
based regimen at our centre [11], with complete B-cell
depletion within 1 month, sustained in half of the patients
at 24 months, and associated prolonged relapse-free
survival.
Our experience suggests that ofatumumab warrants
further investigation as an alternative B celldepleting
agent in AAV. This may be of particular use in patients
who are intolerant of rituximab due to infusion-related re-
actions. Indeed, there is a previous case report of suc-
cessful ofatumumab use in a patient with SLE who
developed anaphylaxis following rituximab infusion [14].
Notably, human anti-chimeric antibodies (HACA) have
been implicated in the generation of infusion reactions
following repeated rituximab exposure (with reported
HACA frequencies of up to 11% in some cohorts [15]),
though their clinical significance is not fully understood.
As a fully humanized antibody, ofatumumab may avoid
immunogenic anti-drug reactions [9], which may have
additional benefits both for tolerability and efficacy after
repeated exposure. Future studies might also explore po-
tential cost benefits of alternative B celldepleting agents;
the cost per course in the UK of using our protocols
equates to £2548 (2  700 mg ofatumumab) vs £3492
(2  1 g rituximab).
Our report has obvious limitations; the cases are small
in number and heterogeneous, and the series is uncon-
trolled. Several patients received CYC in addition to ofa-
tumumab, which may have affected both B cell survival
and clinical response, though it is notable that complete B
cell depletion was observed in both patients who did not
receive concurrent CYC. In addition, the median dose of
CYC administered (3.05 g) was significantly lower than
that reported in published studies using CYC alone as
remission-induction therapy (e.g. 8.2 and 15.9 g in the
pulsed-i.v. and daily-oral groups, respectively, in the
CYCLOPS study [16]). In addition, the inclusion of low-
dose CYC treatment for patients with severe renal disease
is consistent with the use of rituximab in the RITUXVAS
study [2]. Notably, the rapidity, depth and duration of B
cell depletion that we observed in our cohort is greater
than that seen in the published studies using CYC alone
(e.g. <10% of patients in the control limbs of the
RITUXVAS and RAVE studies achieved B cell depletion
within the first month [17, 18]). Collectively, these obser-
vations suggest that a significant proportion of the B
celldepleting and therapeutic effect seen in our cohort
is due to the activity of ofatumumab. We acknowledge,
however, that the synergistic effect of co-administration of
anti-CD20 with low-dose CYC is not fully understood and
requires further investigation.
Finally, we have not examined the utility of ofatumumab
in rituximab-resistant disease, for which there is evidence
of benefit in the treatment of paediatric nephrotic syndrome
and haematological malignancy, potentially due to differ-
ences in drug epitope specificity, pharmacokinetics or the
potential to avoid induction of HACA. Larger studies,
including randomized controlled trials, are clearly needed
to address these questions and to more precisely define
the role of this and other emerging anti-B cell therapies in
AAV. Pending these studies, this series provides a potential
dosing regimen and preliminary evidence that ofatumumab
may be a useful alternative agent in the treatment of AAV.
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